Dipeptidyl Peptidase-4 Inhibition May Stimulate Progression of Carcinoid Tumor
Dipeptidyl peptidase-4 (DPP-4) inhibitors, such as saxagliptin, have gained a rapid growth in use in the treatment of type 2 diabetes mellitus in the past decade. Although they are considered to have a good safety profile, controversy exists regarding their potential to stimulate neoplasm growth. We...
Saved in:
| Main Authors: | Vladimir Pech, Khalid Abusaada, Carlos Alemany |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Case Reports in Endocrinology |
| Online Access: | http://dx.doi.org/10.1155/2015/952019 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Dipeptidyl peptidase 4 inhibition sensitizes radiotherapy by promoting T cell infiltration
by: Yu Tian, et al.
Published: (2023-12-01) -
SAFETY PROFILE OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS
by: M. Ganeva
Published: (2023-03-01) -
Urate-lowering effects of dipeptidyl peptidase-4 inhibitors
by: Taras S. Panevin, et al.
Published: (2020-12-01) -
Effects of Dipeptidyl Peptidase-4 Inhibition with MK-0431 on Syngeneic Mouse Islet Transplantation
by: Jyuhn-Huarng Juang, et al.
Published: (2014-01-01) -
Dipeptidyl peptidase-1 inhibitors in bronchiectasis
by: Emma Johnson, et al.
Published: (2025-06-01)